The Gorringe lab focuses on cancer precision medicine: applying genomics to clinical questions in breast and ovarian cancers.

The guiding principle of our research is that the best health outcomes are attained when our understanding of the disease is deep enough to give treatment tailored to the individual. Such personalisation encompasses:  accurate diagnosis, to be sure of what condition the individual actually has, including cell of origin; an accurate prognosis, to match the aggressiveness of treatment to the risk of recurrence; and an accurately targeted therapy, to give the patient the best chance of recovery with minimal harm from treatment.

The Gorringe lab has an extensive genomics research program to address key precision medicine issues in women’s cancers, including early breast disease and rare ovarian cancer subtypes.

Group Leader, Junior Faculty

Research projects

Personalized Risk Evaluation in breast Ductal Carcinoma in situ (PRECISION)

Ductal carcinoma in situ (DCIS) accounts for 20-25% of breast cancer and is a growing health problem, with great variation in treatment and outcome. After local excision, about 25% of DCIS will recur. There are no robust markers of recurrence risk for tailoring treatment to optimise patient outcome and minimise treatment toxicity. Thus, clinical management of DCIS is challenging and many women are over-treated while others might benefit from more intense therapy or monitoring. We aim to develop a clinical test for personalised DCIS recurrence risk, using gene copy number, immunohistochemistry and gene expression assays. This study will leverage unique local and international DCIS cohorts that have extensive clinical annotation and follow-up data. A similar study for benign breast lesions (atypical ductal hyperplasia and papillomas) is also being undertaken.

Understanding rare ovarian epithelial carcinoma subtypes to improve outcomes

While the genomic profiles of high-grade serous carcinomas have been extensively studied, little is known about the low-grade serous and mucinous subtypes. A major current initiative is the comprehensive Genomic Analysis of Mucinous Tumours (GAMuT) study, which analyses primary ovarian and extra-ovarian metastases with mucinous histology using copy number, expression and exome sequencing. The goals are to identify novel targets for therapy and to determine whether mucinous tumours from multiple tissue origins share genomic characteristics. A similar project is underway in low-grade serous carcinomas.

In addition, we are generating novel in vitro (organoid) and in vivo models for these rare diseases in order to test novel therapies and functionally characterise putative cancer genes.

People

Sakshi Mahale, Research Assistant
Dr Suad Abdirahman, Post-doctoral researcher
Dr Tanjina Kader, Post-doctoral researcher
Carolina Salazar, PhD Student
Abhi Nigam, PhD Student
Masih Sherafitian, PhD Student
Dr Ruwangi Udayasiri, PhD Student
Olivia Craig, Master's Student
Hugo Saunders, Research assistant
Louise Scerri, Scientific Administration Officer

Key publications

Cheasley D, Nigam A, Zethoven M, Hunter SM, Etemadmoghadam D, Semple T, Allan P, Carey mS, Llaurado M, Dawson A, Koeble M, Huntsman DG, Le Page C, Mes-Masson A, Provencher D, Hacker N, Gao Y, AOCS, Bowtell DDL, DeFazio A,  Gorringe KL* Campbell IG* (2020) Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities J. Pathology accepted 1st September 2020

Kang EY, Cheasley D, [40 other co-authors] Köbel K, and Gorringe KL (2020) Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology doi:10.1038/s41379-020-0618-9

Kader T, Elder K, Zethoven M, Semple T, Hill P, Goode DL, Cheasley D, Rowley SM, Byrne DJ, Pang JB, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL. (2020) The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. npj Breast Cancer 6(1):1-13

Gorringe KL, Cheasley D, Wakefield MJ...[30 other co-authors]… Antill YC, Campbell IG, Scott CL (2020) Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology 156(3):552-60

Cheasley D, Wakefield MJ, Ryland GL, [59 other co-authors], Antill YC, Scott CL, Campbell IG, Gorringe KL (2019) The Molecular Origin and Taxonomy of Mucinous Ovarian Carcinoma. Nature Communications. 10(1):3935.

Meagher NS, et al... Gorringe KL, Pharoah PDP, Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Köbel M. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.  Mod Pathol. 2019 Jun 25. doi: 10.1038/s41379-019-0302-0

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. J Pathol. 2019 Jul;248(3):326-338. doi: 10.1002/path.5262

Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG. Molecular comparison of interval and screen-detected breast cancers. J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251

Salazar C, Campbell IG, Gorringe KL. When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy. Front Oncol. 2018 Dec 21;8:654. doi: 10.3389/fonc.2018.00654

Kader T, Hill P, Rakha EA, Campbell IG, Gorringe KL. Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. Breast Cancer Res. 2018 May 2;20(1):39. doi: 10.1186/s13058-018-0967-1

Gorringe KL, Fox SB. Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. Front Oncol. 2017 Oct 23;7:248. doi: 10.3389/fonc.2017.00248

Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL*, Fox SB*. Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features. Clin Cancer Res. 2017 Sep 1;23(17):5210-5217. doi: 10.1158/1078-0432.CCR-17-0743

Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL*, Fox SB*. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21

Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, Byrne D, Fox SB, Mir Arnau G, Tothill RW, Campbell IG, Gorringe KL. Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue. Genome Med. 2016 Nov 15;8(1):121

Pang JM, Gorringe KL, Fox SB. Ductal carcinoma in situ - update on risk assessment and management. Histopathology. 2016 Jan;68(1):96-109. doi: 10.1111/his.12796

Chrysanthou E*, Gorringe KL*, Joseph C, Craze M, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA, Ellis IO, Mukherjee A. Phenotypic characterisation of breast cancer: the role of CDC42. Breast Cancer Res Treat. 2017 Jul;164(2):317-325. doi: 10.1007/s10549-017-4267-8

Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY, Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG (2015). Copy number analysis of ductal carcinoma in situ with and without recurrence. Mod Pathol.28(9):1174-84.

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD, Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG (2015). Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget.6(35):37663-77.

Davis, SJ, Sheppard KE, Anglesio MA, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinksi J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DDL, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL (2015). Enhanced GAB2 expression is associated with improved survival in high-grade serous ovarian cancer and sensitivity to PI3K inhibition. Mol Cancer Ther.14(6):1495-503.

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD, Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL (2015). Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursorsGenome Med.7(1):87.

Ryland GL, Hunter SM, Doyle MA, Rowley SM, Christie M, Allan PE, Bowtell DD, Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG (2013). RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovaryJ Pathol.229(3):469-76.

Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG, Gorringe KL (2012). CONTRA: copy number analysis for targeted resequencingBioinformatics.28(10):1307-13.

Research programs